Eaton Vance Management Crispr Therapeutics Ag Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Eaton Vance Management holds 20,413 shares of CRSP stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,413
Previous 20,413
-0.0%
Holding current value
$1.1 Million
Previous $1.24 Million
7.58%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CRSP
# of Institutions
549Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$441 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$423 Million0.11% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$177 Million0.16% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$177 Million2.23% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$146 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.21B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....